Interview Valles Visio: Nanoligent
In June 2017, researchers from the IIB-Sant Pau, the Institute of Biotechnology and Biomedicine at the UAB and the CIBER-BBN, created a spin-off, Nanoligent, with the goal of developing the first drug...
In June 2017, researchers from the IIB-Sant Pau, the Institute of Biotechnology and Biomedicine at the UAB and the CIBER-BBN, created a spin-off, Nanoligent, with the goal of developing the first drug...
Researchers at the Institut de Recerca de Sant Pau, the Institut de Neurociències de la Universitat Autònoma de Barcelona and the CIBER de Diabetis i Malalties Metabòliques Associades (CIBERDEM) ha...
The Research Group on Inflammation and vascular remodelling of the IIB Sant Pau, led by Dr. Cristina Rodríguez, has recently published the article "Lysyl oxidase (LOX) limits VSMC proliferation and n...
Researchers of the Molecular Physiology Group of the Synapse of the Sant Pau Biomedical Research Institute (IIB Sant Pau), the Autonomous University of Barcelona (UAB), the University of Barcelona and...
El Dr. Jordi Surrallés, director del Servicio de Genética del Hospital y del Grupo de investigación "Síndromes de inestabilidad genómica y reparación del ADN" del Instituto de Investigación de ...